β-CA-specific inhibitor dithiocarbamate Fc14–584B: a novel antimycobacterial agent with potential to treat drug-resistant tuberculosis

Inhibition of novel biological pathways in Mycobacterium tuberculosis (Mtb) creates the potential for alternative approaches for treating drug-resistant tuberculosis. In vitro studies have shown that dithiocarbamate-derived β-carbonic anhydrase (β-CA) inhibitors Fc14–594 A and Fc14–584B effectively...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Enzyme Inhib Med Chem
Autores principales: Aspatwar, Ashok, Hammarén, Milka, Koskinen, Sanni, Luukinen, Bruno, Barker, Harlan, Carta, Fabrizio, Supuran, Claudiu T., Parikka, Mataleena, Parkkila, Seppo
Formato: Artigo
Lenguaje:Inglês
Publicado: Taylor & Francis 2017
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6445161/
https://ncbi.nlm.nih.gov/pubmed/28629306
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14756366.2017.1332056
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares